Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has reported a fruitful first quarter in 2024 with significant milestones such as NASDAQ listing and advancements in their clinical programs, including promising data from a Phase 2b study for knee osteoarthritis treatment. The company’s enhanced financial position and ongoing studies, including the anticipated EP-104GI data for eosinophilic esophagitis, position it for strategic partnerships and further development funding opportunities.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
